Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | HTR1F | P30939 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTR1B | P28222 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18324722 | 0.83 | SLC6A4 (0.53) | HTR2AHTR1FTSHRALDH1A1HTR1B | |
| SCHEMBL8554103 | 0.78 | HTR2C (0.60) | HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL18324679 | 0.77 | KDM4E (0.64) | HTR2AHTR2CALDH1A1KDM4EBRD4 | |
| SCHEMBL9448905 | 0.73 | HTR2A (0.61) | HTR2AHTR2CHTR2B | |
| SCHEMBL24723628 | 0.72 | HTR2A (0.53) | HTR2AHTR2CHTR2B | |
| SCHEMBL18324793 | 0.71 | TDO2 (0.65) | HTR2ACCNT1CDK9HTR1A | |
| SCHEMBL18324804 | 0.71 | TDO2 (0.41) | HTR2AHTR1FCCNT1CDK9HTR1B | |
| SCHEMBL18324762 | 0.71 | OPRM1 (0.58) | HTR2AHTR1FHTR1BHTR1DHTR1A | |
| SCHEMBL18324820 | 0.71 | OPRM1 (0.59) | HTR1FHTR1BHTR1DHTR1A | |
| SCHEMBL18324890 | 0.71 | DRD2 (0.63) | HTR2AHTR2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | HTR2A 511/4885HTR2C 133/4885HTR2B 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.